Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peyman Hadji

Showing results (131-140 of 154) with videos related to

Pageof 16
Sort By:
Geburtshilfe Und Frauenheilkunde|May 31, 2024
Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT RegistryAndreas D Hartkopf, Christina B Walter, Hans-Christian Kolberg, et al.
Geburtshilfe Und Frauenheilkunde|August 29, 2017
Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer RegistryMarkus Wallwiener, Felix Heindl, Sara Y Brucker, et al.
Cancers|October 21, 2020
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with PertuzumabLaura L Michel, Andreas D Hartkopf, Peter A Fasching, et al.
Geburtshilfe Und Frauenheilkunde|December 2, 2020
Correction: Treatment Landscape and Prognosis After Treatment with Trastuzumab EmtansineElena Laakmann, Julius Emons, Florin-Andrei Taran, et al.
Cancers|December 23, 2018
Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer RegistryMichael P Lux, Naiba Nabieva, Andreas D Hartkopf, et al.
Geburtshilfe Und Frauenheilkunde|June 25, 2021
Perimenopause and Postmenopause - Diagnosis and Interventions. Guideline of the DGGG and OEGGG (S3-Level, AWMF Registry Number 015-062, September 2020)Elisabeth C Inwald, Christian Albring, Erika Baum, et al.
BMC Cancer|October 16, 2024
The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtypePhilipp Ziegler, Andreas D Hartkopf, Markus Wallwiener, et al.
Breast (Edinburgh, Scotland)|November 4, 2017
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registryAndreas D Hartkopf, Jens Huober, Bernhard Volz, et al.
Breast (Edinburgh, Scotland)|September 21, 2020
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in GermanyAndreas Schneeweiss, Johannes Ettl, Diana Lüftner, et al.
Breast (Edinburgh, Scotland)|February 14, 2025
Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancerChristina B Walter, Andreas D Hartkopf, Alexander Hein, et al.
Pageof 16

Showing results (131-140 of 154) with videos related to

Sort By:
Pageof 16
Geburtshilfe Und Frauenheilkunde|May 31, 2024
Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT RegistryAndreas D Hartkopf, Christina B Walter, Hans-Christian Kolberg, et al.
Geburtshilfe Und Frauenheilkunde|August 29, 2017
Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer RegistryMarkus Wallwiener, Felix Heindl, Sara Y Brucker, et al.
Cancers|October 21, 2020
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with PertuzumabLaura L Michel, Andreas D Hartkopf, Peter A Fasching, et al.
Geburtshilfe Und Frauenheilkunde|December 2, 2020
Correction: Treatment Landscape and Prognosis After Treatment with Trastuzumab EmtansineElena Laakmann, Julius Emons, Florin-Andrei Taran, et al.
Cancers|December 23, 2018
Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer RegistryMichael P Lux, Naiba Nabieva, Andreas D Hartkopf, et al.
Geburtshilfe Und Frauenheilkunde|June 25, 2021
Perimenopause and Postmenopause - Diagnosis and Interventions. Guideline of the DGGG and OEGGG (S3-Level, AWMF Registry Number 015-062, September 2020)Elisabeth C Inwald, Christian Albring, Erika Baum, et al.
BMC Cancer|October 16, 2024
The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtypePhilipp Ziegler, Andreas D Hartkopf, Markus Wallwiener, et al.
Breast (Edinburgh, Scotland)|November 4, 2017
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registryAndreas D Hartkopf, Jens Huober, Bernhard Volz, et al.
Breast (Edinburgh, Scotland)|September 21, 2020
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in GermanyAndreas Schneeweiss, Johannes Ettl, Diana Lüftner, et al.
Breast (Edinburgh, Scotland)|February 14, 2025
Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancerChristina B Walter, Andreas D Hartkopf, Alexander Hein, et al.
Pageof 16